• Japanese
  • Korean
  • Chinese
Cover Image

Global Obesity Drug Market Analysis

The obesity epidemic has been disseminating among developed countries as well as low-income and middle-income countries. The main factor responsible for the propagation of this disease in the middle and low income countries is the result of new dietary habits and sedentary ways of life, fuelling chronic diseases, and premature mortality. As per WHO, the obese population is forecasted to reach around 700 Million by the end of 2015 from around 500 Million in 2008, which signifies immense opportunities for the players entering this market. Consequently, the obesity drug market is expected to be worth US$ 2.5 Billion by the end of 2014.

According to our report “Global Obesity Drug Market Analysis”, one of the main factors that has been surging the revenue is the heavy R&D spending on the discovery of new drugs. During the last few years, various obesity drugs have been banned by the FDA and various other regulatory bodies on grounds of safety reasons. The drugs have been identified causing serious side effects, such as liver damage, early stage heart disease, and many more. As a result, the drug manufacturers are heavily investing on the research and development of new drugs, which poses minimum or no side effects on the patients.

Further, North America and Europe are expected to be largest obesity drug market as they constitute some of the fattest nations such as, the US, Mexico, Germany etc. As obesity and related morbidities have huge medical costs associated with it, the governments in these regions have been taking rigorous steps to control this pandemic, which further fuels the growth of the market in these regions.

Our report also provides information of the key competitors in the market along with their business information and areas of expertise. The report shows a highly concentrated structure of the market, with the top players dominating the market. It provides segment level analysis of the industry along with the emerging trends that may shape up with the betterment of economic conditions.

The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past, and future performance of the industry. The report provides an extensive research on the recent trends of the global obesity drug market along with an impartial analysis considering the impact of financial crisis on its performance.

Table of Contents

1. Analyst View

2. Research Methodology

3. Understanding Obesity Pandemic

4. Market Trends

  • 4.1. Increasing Prevalence of Obesity
  • 4.2. Heavy R&D Spending
  • 4.3. Strategic Alliances
  • 4.4. Emerging New Treatments
    • 4.4.1. Drug Combos
    • 4.4.2. Cannabinoids
    • 4.4.3. Information and Communication Technologies

5. Global Obesity Drug Market: Industry Performance

  • 5.1. Market Overview
  • 5.2. Major Drugs
    • 5.2.1. Orlistat/Xenical
    • 5.2.2. Meridia
    • 5.2.3. Acomplia
    • 5.2.4. Alli
  • 5.3. Future Obesity Drug Pipeline
    • 5.3.1. Liraglutide
    • 5.3.2. Armodafinil
    • 5.3.3. Sulfamethoxazole/trimethoprim
    • 5.3.4. IHBG-10
  • 5.4. Top Selling Weight-Loss Supplements

6. Regional Level Developments

  • 6.1. North America
    • 6.1.1. US
    • 6.1.2. Mexico
    • 6.1.3. Canada
  • 6.2. Latin America
    • 6.2.1. Brazil
  • 6.3. Europe
    • 6.3.1. UK
    • 6.3.2. France
    • 6.3.3. Germany
  • 6.4. Asia-Pacific
    • 6.4.1. Australia
    • 6.4.2. New Zealand
    • 6.4.3. India
    • 6.4.4. China
  • 6.5. Middle East and Africa
    • 6.5.1. UAE
    • 6.5.2. Qatar
    • 6.5.3. Saudi Arabia
    • 6.5.4. South Africa

7. Competitive Landscape

  • 7.1. F Hoffmann-La Roche Ltd
  • 7.2. Abbott Laboratories
  • 7.3. AstraZeneca Plc
  • 7.4. Sanofi-Aventis SA
  • 7.5. Takeda Pharmaceutical Company Limited

List of Figures:

  • Figure 4-1: Global - Obese Population Aged above 15 Years (Million), 2008 & 2015
  • Figure 5-1: Global - Obesity Drug Market (Billion US$), 2010-2014
  • Figure 5-2: Global - Orlistat/Xenical Sales (Million US$), 2008-2010
  • Figure 5-3: Global - Meridia Sales (Million US$), 2008-2010
  • Figure 5-4: Global - Acomplia Sales (Million US$), 2007 & 2008
  • Figure 5-5: Global - Alli Sales (Million GBP), 2008-2010
  • Figure 6-1: US - Obesity Prevalence (%), 2009 & 2015
  • Figure 6-2: Mexico - Overweight and Obesity Prevalence (%), 2000 & 2006
  • Figure 6-3: Canada - Obese Population (Million), 2007-2009
  • Figure 6-4: Brazil - Obesity Prevalence (%), 2002-03 & 2008-09
  • Figure 6-5: UK - Obesity Prevalence (%), 2009, 2015 & 2025
  • Figure 6-6: UK - Obesity Prevalence in Children (%), 2007-08 to 2009-10
  • Figure 6-7: France - Obesity Prevalence (%), 2003, 2006 & 2009
  • Figure 6-8: Germany - Overweight and Obesity Prevalence (%), 2008
  • Figure 6-9: Australia - Obesity Prevalence (%), 2006-07 & 2007-08
  • Figure 6-10: Australia - Obesity Prevalence in Children Aged 7-15 Years (%), 1985, 1995 & 2007
  • Figure 6-11: New Zealand - Obesity Prevalence (%), 1997, 2003 & 2007
  • Figure 6-12: India - Overweight Prevalence (%), 2005 & 2015
  • Figure 6-13: India - Obesity Drug Market (Billion INR), 2009-2011
  • Figure 6-14: Qatar - Obesity Prevalence (%), 2003, 2005 & 2010

List of Tables:

  • Table 3-1: Risk of Co-morbidities based on BMI Levels
  • Table 6-1: US - Obesity Prevalence by Age Group (%), 2009
  • Table 6-2: Mexico - Overweight and Obesity Prevalence in Children by Age Group (%), 2006
  • Table 6-3: Brazil - Obesity Prevalence by Age Group (%), 2008-09
  • Table 6-4: Australia - Cost of Obesity (Billion US$), 2008-09
  • Table 6-5: South Africa - Overweight Prevalence in Top Cities (%)
  • Table 7-1: F Hoffmann-La Roche Ltd - SWOT Analysis
  • Table 7-2: Abbott Laboratories - SWOT Analysis
  • Table 7-3: AstraZeneca Plc - SWOT Analysis
  • Table 7-4: Sanofi-Aventis SA - SWOT Analysis
  • Table 7-5: Takeda Pharmaceutical Company Limited - SWOT Analysis
Show More
Pricing